In a prospective randomized study, 120 febrile, granulocytopenic patients received as initial therapy ceftazidime with or without teicoplanin. At (48%) given the combination. Lung infiltrates developed in 12 and 13 patients, respectively, but more new infections occurred in the combination group. Allergic skin reactions were also more frequent in this group. Thus, while teicoplanin provides simple, reliable, and safe treatment of patients with presumed gram-positive infections, it is not useful when given empirically to this patient population, and treatment may result in more infective complications and adverse events.
The incidence of gram-positive infections has increased in the last few years as a result of several factors (11, 22) . Selective oral prophylaxis has reduced the incidence of gram-negative infections (3, 12) , while bacteremia caused by coagulase-negative staphylococci has increased, partly as a result of the greater use of indwelling intravenous catheters (6, 21) . Intensification of cytostatic therapy has resulted in extensive damage to the mucosa, particularly of the mouth; consequently, bacteremia caused by viridans group streptococci has assumed greater prominence (2, 13) . Thus, agents specific for gram-positive bacteria, particularly vancomycin, are often added to the initial regimen when fever persists (17) or are included in the initial empiric regimen (18) . Skin reactions and ototoxicity are well known side effects of vancomycin, and nephrotoxicity is more likely to occur when the drug is given concurrently with an aminoglycoside (9) . Teicoplanin is a new glycopeptide antibiotic with activity and structure similar to those of vancomycin, but it can be given once daily with a minimal risk of toxicity (1, 19) . In a previous study, we assessed the utility of adding teicoplanin empirically for a persistent fever (16) . The results showed that only one-third of patients responded. However, the addition was effective in 67% of patients with proven or presumed gram-positive infections and in 78% of those with skin and soft tissue infections (SSTIs). We estimated from these data that only 11% of a general population of febrile, granulocytopenic patients might benefit from the addition of this antibiotic. Therefore, a prospective randomized study was designed to address the question of whether combining * Corresponding author. teicoplanin with ceftazidime for initial empiric therapy might be more effective. To keep the study population as homogeneous as possible, we excluded patients with an infective focus, such as a lung infiltrate, at the onset of fever, since such patients appear to represent a different risk group (5, 8, 10) .
(Preliminary data were presented orally at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, Calif. [I. Novakova 
MATERIALS AND METHODS
The study was designed to compare the efficacy and toxicity of ceftazidime with or without teicoplanin as empiric therapy for febrile, granulocytopenic patients. The investigation received the approval of the Medical Ethics Committee of the University of Nijmegen (1987 -11270, February 1988 . Patients were eligible for this study if they were 14 years old or older, granulocytopenic (granulocyte counts expected to fall to <0.5 x 109/liter), and febrile (single axillary temperature of .38.50C or at least two readings of >38°C taken 2 to 4 h apart), with no obvious focus of infection. In addition, all gave informed consent. They were randomized only once during the same granulocytopenic phase, had received no other parenteral antibiotics before starting therapy, and were nursed in reversed-barrier isolation. The majority of patients had received oral antimicrobial prophylaxis prior to 
RESULTS
Both groups of 50 patients were similar in terms of sex, age, and underlying disease, with more than 75% being treated for leukemia (Table 1 ). There were nine unassessable episodes in the ceftazidime group. Two patients died of cerebral hemorrhage, and another died within 6 h of admission because of Escherichia coli sepsis. Four patients were ineligible: two were not granulocytopenic, one had a lung infiltrate, and another had an infected postoperative wound. There were also two protocol violations (one patient who was randomized for the second time during the same pancytopenic phase and one for whom therapy was stopped prematurely). In the combination group, eight episodes were deemed unassessable. One patient died of a lung hemorrhage, one had been treated with other antibiotics before randomization, and one never became granulocytopenic. The remaining episodes were protocol violations (two patients who were randomized for the second time during the same pancytopenic phase and three for whom therapy was stopped prematurely). Therefore, 51 febrile episodes in the ceftazidime group and 52 in the combination group were assessable. Both treatment groups were comparable in terms of granulocytes at entry, the onset of fever, and the total period of granulocytopenia. On (Fig. 1) . Approximately half of the patients in each group became afebrile within 72 h after therapy was started, and the majority responded before granulocyte recovery (Table 3) . Both groups were comparable in terms of the duration of fever, antibiotic therapy, and the duration of both total granulocytopenia and granulocytopenia following defervescence.
Initial therapy was modified in 26 patients (51%) treated with ceftazidime and in 19 patients (37%) treated with the combination. Eleven patients in the monotherapy group and 10 in the combination group had bacteremia. Twenty patients (39%) in the monotherapy group and 15 (29%) in the combination group responded after the modification of therapy; 8 and 11 patients, respectively, did so after the first modification. Of ceftazidime-treated patients given teicoplanin as the first modification, only 7 LRTIs accounted for 12 (41%) versus 13 (36%), FUOs accounted for 7 (24%) versus 13 (36%), and SSTIs accounted for 1 versus 4 events in the monotherapy and combination groups, respectively. There were also four bacteremic episodes and one case of a brain abscess in each group. Abdominal complications and sinusitis represented the remainder.
Adverse events and safety evaluation. An increase of 50% or more in serum creatinine levels was seen in three patients treated with monotherapy and in four treated with the combination. Normal kidney function was restored after the cessation of therapy in two and three patients, respectively.
A greater-than-threefold increase in alkaline phosphatase, bilirubin, and/or transaminase levels was found in 10 patients treated with monotherapy and in six treated with the combination. These changes were reversible after the cessation of therapy in five and three patients, respectively.
Two patients in the ceftazidime group experienced an allergic skin reaction, as did eight in the combination group (Fisher's exact test; P = 0.04). The rash appeared to be related to the study drugs in neither patient treated with monotherapy and in five patients treated with the combination (Fisher's exact test; P = 0.03). One case was probably caused by ceftazidime, since subsequent administration of the drug as a sole treatment resulted in the reappearance of the rash. Teicoplanin appeared to be responsible for the exanthema in another case, since further therapy with ceftazidime alone was uneventful. It was not possible to determine which of the drugs was responsible in the remaining three cases.
Patients given ceftazidime alone were thrombocytopenic (<20 x 109/liter) for 22.5 ± 4.6 days, and those given both drugs were thrombocytopenic for 19.9 ± 5.2 days. The requirement for thrombocytes during treatment with ceftazidime plus teicoplanin was similar to that during treatment with ceftazidime alone (mean numbers of thrombocyte transfusions, 8.4 ± 3.3 and 7.8 ± 2.1, respectively).
Complete audiograms were obtained for 29 patients treated with the combination, and no changes were recorded between the measurements obtained before and during the treatment.
Pooled data from both treatment groups. Of 103 febrile granulocytopenic episodes, 12 (11.6%) resulted in death and 58 (56%) were managed successfully with either of the initial regimens alone. Thirty-eight percent of episodes were accompanied by bacteremia, 79% being caused by grampositive bacteria. Forty-four percent of patients experienced one or more subsequent infective events on average 7.4 ± 1.4 days after the onset of the initial fever, with 75% of these events developing between 4 and 9 days. One in four patients developed an infection subsequent to an LRTI. Fever persisted for five or more days in 38% of patients, and its mean duration was similar for patients with an initial FUO or gram-positive bacteremia (7.3 ± 1.9 versus 9.7 ± 3.9 days, respectively; P = 0.3), but patients who developed an LRTI were febrile significantly longer (17.5 ± 4.1 days; P c 0.01).
Patients who responded without modifications were granulocytopenic for a significantly shorter period than were those who responded after modifications: 18.3 ± 2.6 versus 26.1 ± 4.5 days, respectively (P < 0.01). However, the periods of thrombocytopenia (<20 x 109/liter) were essentially the same. Of patients responding to initial therapy, 53% ± 13% defervesced within 72 h, as compared with only 2% ± 4% of those responding to modified therapy (P < 0.01). Those given initial therapy only were febrile for 3.8 ± 0.2 days, and those who needed additional antibiotics were febrile for 11.7 ± 0.7 days (P < 0.01). The latter were also less likely to respond before granulocyte recovery (49% + 15% versus 78% ± 11%, respectively [P < 0.01]) and more likely to have a subsequent infective event (71% ± 13% versus 22% ± 11%, respectively [P < 0.01]).
DISCUSSION
This study was designed to investigate the utility of adding teicoplanin to ceftazidime at the outset for the initial therapy of an FUO or bacteremia occurring during granulocytopenia, More patients given the combination responded to therapy without modifications than did those given ceftazidime alone. However, there were more instances of new infections in the combination group, two of these resulting in death. Most deaths occurred 7 or more days after empiric therapy was begun and all after modifications of one sort or another. The initial infection was responsible for one death, despite early modification with amikacin. The patient had persistent bacteremia caused by E. cloacae, an organism likely to present problems for any patient given ceftazidime as the only anti-gram-negative bacterial antibiotic if, as in this case, the strain is resistant or possesses a derepressible ,-lactamase. Clinical deterioration might have been prevented in the two patients with bacteremia caused by viridans group streptococci had they been treated initially with both ceftazidime and teicoplanin. Therapy was changed more often and earlier in the ceftazidime group, mainly because of what was regarded as persistent fever. This change might have been due to a genuine lack of efficacy were it not for the fact that the proportions of patients with persistent fever were similar in both groups. Since only a minority of patients with a serious infection will defervesce within 72 h (20) , fever sustained for at least 4 or perhaps 5 days might in fact provide a more appropriate decisionmaking point. The durations of fever were similar in both treatment groups, including patients who had initial grampositive bacteremia, and the majority of the cases of bacteremia were cleared before eventual modifications were made.
Thus, the response rate was dependent on whether the clinician perceived it to be necessary to modify the initial treatment rather than on there being clear reasons for doing so. The modifications were done earlier in the monotherapy group because the clinician was inclined to augment the anti-gram-positive bacterial spectrum of ceftazidime more readily than to augment that of the combination, given that infection was more likely to be caused by these bacteria than by gram-negative bacteria. Indeed, the day on which a drug other than teicoplanin was added to ceftazidime was comparable to the day on which the first modification was done in the combination group. In light of these facts, the larger number of modifications made to monotherapy does not reflect a lack of efficacy but rather an element of uncertainty on the part of the clinician. This phenomenon is not peculiar to our study but has been encountered before, in both our center and others, but usually the exact reasons for changing the therapy have not been stated (7). These observations tend to support the conclusion that the strategy for management is influenced by the choice of initial therapy insofar as the clinician has the option of adding a specific anti-grampositive bacterial agent to ceftazidime alone but is obviously denied this option when the patient has already started taking that agent. To avoid this bias, a study such as this one would have had to have been blinded and placebo controlled. This solution would be both complicated and expensive, but if the results of treatment are liable to be influenced strongly by observer effects, then the benefits outweigh the costs.
Patients given therapy modifications were granulocytopenic significantly longer than were those responding to the initial regimens. Furthermore, they were febrile longer, experienced more infective events, and received more therapy. They were also more likely to die, and the infections tended to resolve only after granulocyte recovery. These differences had more impact on outcome than had initial therapy, but apart from persistent fever, there is little to aid the clinician in defining this group prospectively. Nevertheless, these patients clearly represent a different risk group, possibly because of their longer period of granulocytopenia. It is clear that those who continue to have fever beyond the initial therapy period are likely to develop further infective complications, whereas those who respond early are not. Patients who remain persistently febrile or develop a second fever usually do so because of a subsequent infection unrelated to the presence of the initial bacteremia. Diagnosis and treatment are difficult, and the fact that most complications occur within 9 days of the start of the initial therapy demonstrates a clear need for sustained clinical attention. Currently, around 30 to 40% of leukemic patients fall into this category (14) .
Our repeated failure to isolate bacteria in these patients suggests another etiology, especially in cases in which a lung infiltrate developed. These cases were associated with persistent fever and a mortality of 41% and were mostly of fungal etiology (in cases that were documented). Patients with lung infiltrates also remained febrile for a longer period than did those with either initial bacteremia or an FUO. Thus, the initial infection did not appear to be prognostic for either further infective complications or the ultimate outcome.
More patients treated initially with ceftazidime and teicoplanin than with monotherapy developed a subsequent infection during the whole granulocytopenic phase, mainly an SSTI and a second FUO. The difference could not be explained by the duration of granulocytopenia or total fever or by the total number of antimicrobial drugs given as modifications. However, subsequent infective events developed more frequently in patients treated with two drugs initially than in patients treated with monotherapy modified by one drug, suggesting that the initial treatment of a granulocytopenic patient with more than one antibiotic may be complicated by a higher risk of a subsequent infection.
Concentrations of teicoplanin in serum were within the expected range, and there were few interpatient variations (1) . There was neither evidence of major teicoplanin-related toxicity nor evidence of any obvious adverse effects on bone marrow recovery in terms of the return of thrombocytes and leukocytes or with regard to ototoxicity. Notwithstanding the greater number of allergic skin reactions attributable to the combination, teicoplanin still appears to offer a safe alternative to vancomycin when'an anti-gram-positive bacterial agent is required.
The results of our study showed that the addition of teicoplanin at the outset to ceftazidime did not markedly alter the final outcome in febrile granulocytopenic patients. We acknowledge that to detect reliably a difference of 15%, given initially. The prevalence of infections caused by grampositive bacteria, such as in cases of line-associated infections, should be one of the determinants in deciding whether to add a specific agent at the outset. The mortality and morbidity associated with postponing the administration of a glycopeptide antibiotic must also be taken into account. In our patient population, these were relatively low, as was also the case in other studies (14, 17) , but the risk of superinfection was higher in the two-drug treatment group. This risk indicates that one should only add a specific agent when required, although others have argued to the contrary (4, 18) . Each center must know its own epidemiology and make its own decisions in light of the published data.
In conclusion, our results show that the addition of teicoplanin to initial empiric therapy is unnecessary in patients with presumed bacteremia without specific signs and symptoms of gram-positive infections. Its use may also lead to more infective complications and adverse events. However, when indicated, the drug is both effective and relatively safe.
